Want to see AVTR full AI Analyst Report?
Adjusted Operating Income by Segment
Reveals profitability across different business segments, helping investors assess which areas are driving earnings and where there might be challenges or opportunities for improvement.Over 2023–25 the legacy Laboratory Solutions and Bioscience Production lines saw steady erosion in adjusted operating income from volume, mix and margin pressures; Q1 2026 shows a structural reclassification into VWR Distribution & Services and Bioscience & Medtech Products, with both immediately reporting stronger operating results—supporting management’s view that VWR has bottomed and BMP order trends are improving. Corporate costs remain a recurring drag, and execution risks (freight/mix, customer prebates and a modest Middle East inflation headwind) mean the Revival program must deliver to convert this stabilization into sustained H2 organic growth.
Date | Laboratory Solutions | Bioscience Production | Corporate | Bioscience & Medtech Products | VWR Distribution & Services |
|---|---|---|---|---|---|
Jun 30, 2026 | $0.00 | $0.00 | -$18.90M | $117.60M | $126.40M |
Mar 31, 2026 | $0.00 | $0.00 | -$17.50M | $102.70M | $105.40M |
Dec 31, 2025 | $114.50M | $127.00M | -$16.00M | $0.00 | $0.00 |
Sep 30, 2025 | $123.60M | $127.70M | -$14.00M | $0.00 | $0.00 |
Jun 30, 2025 | $133.30M | $139.70M | -$20.80M | $0.00 | $0.00 |
Mar 31, 2025 | $139.00M | $123.40M | -$19.60M | $0.00 | $0.00 |
Dec 31, 2024 | $147.40M | $149.20M | -$17.20M | $0.00 | $0.00 |
Sep 30, 2024 | $151.50M | $138.10M | -$14.80M | $0.00 | $0.00 |
Jun 30, 2024 | $150.90M | $144.00M | -$17.70M | $0.00 | $0.00 |
Mar 31, 2024 | $148.20M | $126.90M | -$16.70M | $0.00 | $0.00 |